BioVie Inc.BIVINASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Loading chart...

Alerts

Want to monitor BIVI?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Create free account to monitor BIVI

Key Statistics

About

BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s).

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology

www.biovieinc.com →

News

IES Holdings: Electrified In 2026

seekingalpha.com

Aptiv Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

benzinga.com

Italy's Intesa targets higher 2026 profit after beating forecast in last quarter

reuters.com

European stocks set for sharp declines as global market fears are reignited

cnbc.com

The Best Stocks to Invest $10,000 in to Start 2026

fool.com

EV maker Polestar secures $400 million equity funding

reuters.com

CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)

globenewswire.com

Julius Baer reports net profit of $988 million for 2025

reuters.com

Abercrombie & Fitch: Pullback Creates Another Opportunity

seekingalpha.com

Exclusive: Barry Callebaut CEO left after high-level split over cocoa, sources say

reuters.com

S&P 500 Declines For Third Consecutive Session But Records Gain In January: Investor Sentiment Declines, Fear Index Remains In 'Greed' Zone

benzinga.com

Sanofi's genetic disorder drug shows mixed results in late-stage trials

reuters.com

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

benzinga.com

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

globenewswire.com

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?

fool.com

Millicom International Cellular: The Turnaround Is Over - The Cash Flow Rerating Begins

seekingalpha.com

Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy

seekingalpha.com

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

Key Statistics

About

News

IES Holdings: Electrified In 2026

Aptiv Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Kosmos Energy to Host Fourth Quarter 2025 Results and Webcast on March 2, 2026

My Top Artificial Intelligence (AI) Stocks to Buy in 2026

Julius Baer Posts Expected Drop in Profit

Italy's Intesa targets higher 2026 profit after beating forecast in last quarter

European stocks set for sharp declines as global market fears are reignited

The Best Stocks to Invest $10,000 in to Start 2026

EV maker Polestar secures $400 million equity funding

CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)

Julius Baer reports net profit of $988 million for 2025

Abercrombie & Fitch: Pullback Creates Another Opportunity

Exclusive: Barry Callebaut CEO left after high-level split over cocoa, sources say

S&P 500 Declines For Third Consecutive Session But Records Gain In January: Investor Sentiment Declines, Fear Index Remains In 'Greed' Zone

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?​

Millicom International Cellular: The Turnaround Is Over - The Cash Flow Rerating Begins

Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy

Explore More

IES Holdings: Electrified In 2026

Aptiv Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Kosmos Energy to Host Fourth Quarter 2025 Results and Webcast on March 2, 2026

My Top Artificial Intelligence (AI) Stocks to Buy in 2026

Julius Baer Posts Expected Drop in Profit

Italy's Intesa targets higher 2026 profit after beating forecast in last quarter

European stocks set for sharp declines as global market fears are reignited

The Best Stocks to Invest $10,000 in to Start 2026

EV maker Polestar secures $400 million equity funding

CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)

Julius Baer reports net profit of $988 million for 2025

Abercrombie & Fitch: Pullback Creates Another Opportunity

Exclusive: Barry Callebaut CEO left after high-level split over cocoa, sources say

S&P 500 Declines For Third Consecutive Session But Records Gain In January: Investor Sentiment Declines, Fear Index Remains In 'Greed' Zone

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?​

Millicom International Cellular: The Turnaround Is Over - The Cash Flow Rerating Begins

Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy

Key Statistics

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?